VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS COMPARISON ★

NO ADVICE

Wednesday, January 14, 2026

Stock Comparison

AbbVie Inc. vs Abbott Laboratories

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

AbbVie Inc.

ABBV · New York Stock Exchange

Market cap (USD)$389B
Gross margin (TTM)
Operating margin (TTM)
Net margin (TTM)
SectorHealthcare
Industry
CountryUS
Data as of2026-01-11
Moat score
65/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into AbbVie Inc.'s moat claims, evidence, and risks.

View ABBV analysis

Abbott Laboratories

ABT · New York Stock Exchange

Market cap (USD)$219.2B
Gross margin (TTM)54%
Operating margin (TTM)17.7%
Net margin (TTM)31.9%
SectorHealthcare
IndustryMedical - Devices
CountryUS
Data as of2025-12-30
Moat score
64/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Abbott Laboratories's moat claims, evidence, and risks.

View ABT analysis

Comparison highlights

  • Moat score gap: AbbVie Inc. leads (65 / 100 vs 64 / 100 for Abbott Laboratories).
  • Segment focus: AbbVie Inc. has 6 segments (47.4% in Immunology); Abbott Laboratories has 7 segments (26.7% in Cardiovascular & Electrophysiology Devices).
  • Moat breadth: AbbVie Inc. has 3 moat types across 2 domains; Abbott Laboratories has 10 across 3.

Primary market context

AbbVie Inc.

Immunology

Market

Immunology therapies for autoimmune diseases (biologics and small molecules; e.g., IL-23, JAK, TNF)

Geography

Global

Customer

Prescribing specialists (rheumatology, dermatology, gastroenterology), payers (PBMs/insurers), patients

Role

Innovator biopharma (R&D, clinical development, regulated manufacturing, commercialization)

Revenue share

47.4%

Abbott Laboratories

Cardiovascular & Electrophysiology Devices

Market

Cardiovascular, electrophysiology, rhythm management, structural heart and heart failure devices

Geography

Global

Customer

Hospitals, ambulatory surgery centers, cardiologists/electrophysiologists

Role

Implantable device manufacturer

Revenue share

26.7%

Side-by-side metrics

AbbVie Inc.
Abbott Laboratories
Ticker / Exchange
ABBV - New York Stock Exchange
ABT - New York Stock Exchange
Market cap (USD)
$389B
$219.2B
Gross margin (TTM)
n/a
54%
Operating margin (TTM)
n/a
17.7%
Net margin (TTM)
n/a
31.9%
Sector
Healthcare
Healthcare
Industry
n/a
Medical - Devices
HQ country
US
US
Primary segment
Immunology
Cardiovascular & Electrophysiology Devices
Market structure
Oligopoly
Oligopoly
Market share
n/a
n/a
HHI estimate
n/a
n/a
Pricing power
Moderate
Moderate
Moat score
65 / 100
64 / 100
Moat domains
Legal, Demand
Demand, Legal, Supply
Last update
2026-01-11
2025-12-30

Moat coverage

Shared moat types

IP Choke PointBrand Trust

AbbVie Inc. strengths

Regulated Standards Pipe

Abbott Laboratories strengths

Procurement InertiaInstalled Base ConsumablesData Workflow LockinGovernment Contracting RelationshipsCompliance AdvantageDistribution ControlScale Economies Unit CostTraining Org Change Costs

Segment mix

AbbVie Inc. segments

Full profile >

Immunology

Oligopoly

47.4%

Oncology

Competitive

11.6%

Neuroscience

Competitive

16%

Aesthetics

Oligopoly

9.2%

Eye Care

Competitive

4%

Other Key Products

Competitive

11.9%

Abbott Laboratories segments

Full profile >

Established Pharmaceutical Products

Competitive

12.4%

Diagnostic Products

Oligopoly

22.3%

Pediatric Nutrition

Oligopoly

9.6%

Adult Nutrition

Oligopoly

10.5%

Diabetes Care (CGM & glucose monitoring)

Duopoly

16.2%

Cardiovascular & Electrophysiology Devices

Oligopoly

26.7%

Neuromodulation Devices

Oligopoly

2.3%

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Looking for expansion-stage stocks?

Proven models entering the expansion stage with unit economics that work.

View expansion-stage stocks

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.